Recognizing asthma risk scenarios: individualized inhaler usage and inhalation parameter profiles from an electronic inhaler with integrated sensors
Conclusions: Objective data from the DS offer opportunities to identify individual asthma patients with elevated risk of adverse asthma outcomes. Real-time identification of these high-risk patterns may allow clinicians and patients to intervene early and prevent future asthma exacerbations. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Levy, M. L., Hoyte, F., Mosnaim, G., Wechsler, M., Safioti, G., Magnus, N., Sagalovich, K., Bosnic-Anticevich, S., Kocks, J. Tags: Monitoring airway disease Source Type: research

Characteristics of patients with asthma using single inhaler triple therapy (SITT) in the USA
Conclusions: Differences in baseline clinical characteristics were noted between TT100/200 groups, with older and more severe patients initiating high dose FF/UMEC/VI.Funding: GSK (217417) (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Noorduyn, S. G., Kahle-Wrobleski, K., Paczkowski, R., Lee, L., Veeranki, P., Johnson, M., Ismaila, A. S., Igboekwe, E., Nack, J., Gronroos, N. N. Tags: Airway pharmacology and treatment Source Type: research

Heterogeneous treatment effect estimation of LABA/LAMA/ICS on COPD exacerbation risk in the IMPACT trial
We aimed to identify heterogeneity in the treatment effect of triple therapy (LABA/LAMA/ICS) compared to dual therapy (LABA/LAMA) for COPD exacerbation risk.We used data from subjects in the fluticasone furoate/umeclidinium/vilanterol (FF/U/V, n=3989) and U/V (n=2001) arms in the IMPACT trial (NCT02164513). Subjects were split (70:30) in a training (n=4193) and independent test set (n=1797). We applied survival analysis on time-to-first exacerbation and compared Cox proportional hazards model (CPH, one model for both arms) with machine learning model Random Survival Forest (RSF, one model for each arm). The models were tra...
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Verstraete, K., Gyselinck, I., Huts, H., De Vos, M., Janssens, W. Tags: Airway pharmacology and treatment Source Type: research

Economic benefit of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) by baseline blood eosinophil (EOS) count in COPD in the UK - The IMPACT trial
Conclusions: FF/UMEC/VI is expected to be a cost-effective treatment option for COPD patients in the UK, irrespective of baseline blood EOS count.Funding: GSK 206973 (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Ismaila, A. S., Shah, D., Martin, A., Kendall, R., Noorduyn, S. G., Dasari, P., Risebrough, N. A., Compton, C., Noorduyn, S. G. Tags: Airway pharmacology and treatment Source Type: research

Characteristics of COPD patients initiating budesonide/glycopyrronium/formoterol (BGF) and other triple therapy in Japan: a health-care claims-based real-world database study (MITOS program)
Conclusions: The proportion of asthma+COPD patients was high among those initiating TT, especially MITT. Patients using BGF in the first 12 months after market approval had a higher history of exacerbations. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Takahashi, K., Makita, N., Castaneda, J., Argoubi, R., Nowacki, G., Issa, S., Matsumoto, I., Yoshida, Y., Mullerova, H. Tags: Airway pharmacology and treatment Source Type: research

Serum inhaled corticosteroid levels in patients with severe asthma.
There are no robust methods of assessing compliance to inhaled corticosteroid (ICS) therapy. Medication possession ratio calculated based on dispensed prescriptions is often used but does not account for whether the medication was taken, and if so correctly. We explored the feasibility of measuring serum ICS levels in patients with severe asthma on biologics.Patients with severe asthma approved for mepolizumab were invited. Patients were instructed to withhold their ICS on the morning of the first visit for spirometry, but to continue their prescribed ICS for the remainder of the study. Serum was taken approximately four h...
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Pang, Y. L., Ali, M., Fowler, S. J., Keevil, B., Mckeever, T., Sayers, I., Shaw, D. E. Tags: Airway pharmacology and treatment Source Type: research

Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence?
CONCLUSIONS: Current evidence supports long-term treatment with novel corticosteroid formulations, challenging the established treatment paradigm of EoE. BOT appears to be the most effective steroid therapy, although head-to-head comparative trials between STCs are needed.PMID:37814560 | DOI:10.51821/86.3.11757 (Source: Acta Gastro-Enterologica Belgica)
Source: Acta Gastro-Enterologica Belgica - October 10, 2023 Category: Gastroenterology Authors: S Walgraeve T Vanuytsel Source Type: research